Companies › Climb Bio
2 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Genitourinary, Hematology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Budoprutug (TNT119) | – | Phase 2 | Primary Membranous Nephropathy; Systemic Lupus Erythematosus; Immune Thrombocytopenia (ITP); Systemic Lupus Erthematosus | Apr 2027 |
| CLYM116 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07248865 | CLYM116 | Phase 1 | Healthy Volunteers | Genitourinary | Jul 2026 |
| NCT07011043 | Budoprutug (TNT119) | Phase 1 | Systemic Lupus Erythematosus | Immunology | Apr 2027 |
| NCT07043946 | Budoprutug (TNT119) | Phase 1 | Immune Thrombocytopenia (ITP) | Hematology | Aug 2027 |
| NCT07564596 | Budoprutug (TNT119) | Phase 1 | Systemic Lupus Erthematosus | Immunology | Sep 2027 |
| NCT07096843 | Budoprutug (TNT119) | Phase 2 | Primary Membranous Nephropathy | Genitourinary | Oct 2027 |
Cash and short-term investments of $205m on 2026-09-30; operating cash outflow about $50m a year; runway about 50 months at that burn, to Nov 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Omeros Akebia Therapeutics Jade Biosciences Neurocrine Switzerland ScinnoHub Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.